vTv Therapeutics
VTVT
41 hedge funds and large institutions have $23.7M invested in vTv Therapeutics in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
31% more capital invested
Capital invested by funds: $18M → $23.7M (+$5.67M)
0.03% less ownership
Funds ownership: 0.96% → 0.93% (-0.03%)
7% less funds holding
Funds holding: 44 → 41 (-3)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.39M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$798K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$570K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$227K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$966K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$157K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$59K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$49.9K |
| 5 |
Morgan Stanley
New York
|
-$36.5K |
VTVT Hedge Fund Activity: Q1 2017 in Review
41 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2017, worth a combined $23.7M — up 31% from $18M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VTVT positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $2.39M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $966K sold.
- 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2017, down from 44 in Q4 2016.
- Funds reported $23.7M of vTv Therapeutics stock for Q1 2017, up 31% quarter-over-quarter.
- 8 funds opened new vTv Therapeutics positions in Q1 2017 and 5 closed out, a net change of +3 holders.
- The largest vTv Therapeutics buyer in Q1 2017 was BlackRock, an estimated $2.39M added.
- The largest vTv Therapeutics seller in Q1 2017 was Ghost Tree Capital, an estimated $966K sold.
Based on aggregated 13F filings for Q1 2017.